Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy

Bibliographic Details
Main Authors:	Ricchi Paolo, Cracolici Eliana, Pepe Pasquale, Centra Michele, Pitrolo Lorella, Capra Marcello, Caruso Vincenzo, Dell'Amico Maria, Rossi Giuseppe, Meloni Antonella, Pepe Alessia, Lombardi Massimo
Format:	Article
Language:	English
Published:	Elsevier 2011-02-01
Series:	Journal of Cardiovascular Magnetic Resonance

Similar Items

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
by: Borgna-Pignatti Caterina, et al.
Published: (2011-02-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01)

Survival and desferrioxamine in thalassaemia major.
by: Modell, B, et al.
Published: (1982)

Cataract Formation due to use of Deferiprone in a Patient with Thalassemia Major
by: Barbaros sahin Karagun, et al.
Published: (2015-03-01)

Importance of Desferrioxamine Susceptibility in Identification of Staphylococcus epidermidis
by: Gülay KORUKLUOĞLU, et al.
Published: (1997-03-01)

Dual Role of Desferrioxamine in Erwinia amylovora Pathogenicity
by: Alia Dellagi, et al.
Published: (1998-08-01)

EFFECTS OF IRON AND DESFERRIOXAMINE ON THE GROWTH OF PLASMODIUM-FALCIPARUM INVITRO
by: Peto, T, et al.
Published: (1987)

Thalassaemia major: the murky story of deferiprone.
by: Savulescu, J
Published: (2004)

Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans.
by: Ren, X, et al.
Published: (2000)

Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment
by: Dahlui, M., et al.
Published: (2009)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
by: Gotsis Efstathios D, et al.
Published: (2011-07-01)

WHAT A HİGH FREQUENCY OF DEFERİPRONE-İNDUCED AGRANULOCYTOSİS İN A TURKİSH POPULATİON OF THALASSEMİA MAJOR
by: Mehmet Helvacı, et al.
Published: (2015-03-01)

Effects of riboflavin and desferrioxamine B on Fe(II) oxidation by O2
by: Peng Zhang, et al.
Published: (2022-03-01)

<i>Salmonella</i> Typhimurium and <i>Pseudomonas aeruginosa</i> Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
by: Serena Ammendola, et al.
Published: (2021-09-01)

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)
by: M Elalfy, et al.
Published: (2022-01-01)

Antiplatelet activity of deferiprone through cyclooxygenase-1 inhibition
by: Ngan Thi Tran, et al.
Published: (2020-05-01)

Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1.
by: Balanos, G, et al.
Published: (2002)

Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias
by: Lee, Way Seah, et al.
Published: (2011)

Chemoenzymatic Synthesis of Select Intermediates and Natural Products of the Desferrioxamine E Siderophore Pathway
by: Katherine M. Hoffmann, et al.
Published: (2022-09-01)

Single centre retrospective study of patients receiving desferrioxamine through PICC line
by: Shruti Kakkar, et al.
Published: (2022-01-01)

Desferrioxamine Supports Metabolic Function in Primary Human Macrophages Infected With Mycobacterium tuberculosis
by: James Joseph Phelan, et al.
Published: (2020-05-01)

Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patients
by: Quarta Antonella, et al.
Published: (2010-01-01)

Effects of Salinomycin and Deferiprone on Lead-Induced Changes in the Mouse Brain
by: Emilia Petrova, et al.
Published: (2023-02-01)

Solubility and thermodynamic study of deferiprone in propylene glycol and ethanol mixture
by: Samira Radmand, et al.
Published: (2023-04-01)

Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
by: Sujian Xia, et al.
Published: (2013-01-01)

Desferrioxamine biosynthesis: diverse hydroxamate assembly by substrate-tolerant acyl transferase DesC
by: Ronan, JL, et al.
Published: (2018)

The Iron Chelator Desferrioxamine Increases the Efficacy of Bedaquiline in Primary Human Macrophages Infected with BCG
by: Christina Cahill, et al.
Published: (2021-03-01)

Different patterns of myocardial iron overload by multislice T2* Cardiovascular MR as markers of risk for cardiac dysfunction in thalassemia major
by: Lombardo Massimo, et al.
Published: (2011-02-01)

A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients
by: Mohammad Rohani, et al.
Published: (2018-02-01)

Talasemi Majörlü Bir Hastada Deferipron Kullanımına Bağlı Gelişen Katarakt
by: Barbaros KARAGÜN, et al.
Published: (2015-10-01)

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India
by: Isita Tripathy, et al.
Published: (2022-09-01)

A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum 'in vitro': the unimportance of serum iron.
by: Peto, T, et al.
Published: (1986)

Effects of iron concentration and DFB (Desferrioxamine-B) on transcriptional profiles of an ecologically relevant marine bacterium
by: Gary R. LeCleir, et al.
Published: (2023-01-01)

Radiochemistry and Preclinical PET Imaging of Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen
by: Eleni Gourni PhD, et al.
Published: (2017-10-01)

Bibliometric Review on New Possibilities of Antimycobacterial Agents: Exploring Siderophore Desferrioxamine’s Applications as an Antimicrobial Agent
by: Patrícia Vieira de Oliveira, et al.
Published: (2023-09-01)

Chitogel with deferiprone following endoscopic sinus surgery: improved wound healing and microbiome
by: Anna Megow, et al.
Published: (2024-04-01)

Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone
by: Viktor A. Timoshnikov, et al.
Published: (2020-05-01)

Identifying a Deferiprone–Resveratrol Hybrid as an Effective Lipophilic Anti-Plasmodial Agent
by: Supawadee Maneekesorn, et al.
Published: (2021-07-01)

Evaluation of Hearing Threshold in Patients with Beta Thalasemia Major Receiving Regular ChelationTherapy with Desferrioxamine (DFO)
by: K Mozafarinia, et al.
Published: (2005-03-01)